Clinical Trial Update: Safety and Activity of IMAB362 in Combination With Zoledronic Acid and Interleukin-2 in CLDN18.2-positive Gastric Cancer [Phase 1]

View source ↗

Summary

Phase 1 study assessing safety and activity of IMAB362 (zolbetuximab) in combination with zoledronic acid and interleukin-2 in CLDN18.2-positive gastric, GEJ, a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma of the Gastroesophageal Junction
• Esophageal Adenocarcinoma
• Gastric Adenocarcinoma
• Gastric Cancer

Drugs mentioned

• IMAB362 (zolbetuximab)
• Interleukin-2 (interleukin-2)
• Zoledronic acid (Zoledronic acid)

Snippet

Sponsor: Astellas Pharma Global Development, Inc. | Conditions: CLDN18.2-positive Gastric Adenocarcinoma, CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction | Phase 1 | Status: COMPLETED